We asked Professor Stefan N. Symeonides, one of the authors of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024.
Adjuvant treatment with pembrolizumab has significantly improved overall survival in patients with clear cell renal cell carcinoma who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial.
Video: https://medicaldigest.org/scientific-contents/standalonecontent:overall-survival-results-keynote-564
